Filing Flows › Akebia Therapeutics (AKBA) › Q2 2026 › vs Q1 2026
Akebia Therapeutics (AKBA) Q2 2026 vs Q1 2026 (quarter over quarter)
Akebia Therapeutics's revenue fell $4.4M (-8%) from $53.5M in Q1 2026 to $49.1M in Q2 2026.
Akebia Therapeutics, Q2 2026: revenue $49.1M (-21% year over year), operating margin -12.9%, net loss $8.9M, operating cash flow $3.5M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.0% | -39.7% | +44.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $49.1M | $53.5M | −$4.4M | -8% |
| Net loss | $8.9M | $9.1M | −$146K | -2% |
| Costs & expenses | $58.0M | $62.6M | −$4.6M | -7% |
| Operating costs | $55.5M | $58.2M | −$2.8M | -5% |
| Interest & other, net | $2.5M | $4.2M | −$1.7M | -41% |
| Income tax | $70K | $126K | −$56K | -44% |
| Cost of revenue | $10.4M | $12.3M | −$1.9M | -15% |
| Research & development | $14.1M | $14.8M | −$748K | -5% |
| SG&A | $28.2M | $30.4M | −$2.3M | -7% |
| Other operating costs | $2.8M | $707K | $2.1M | +296% |
| Operating cash sources | $12.4M | −$12.2M | $24.6M | — |
| Depreciation | $585K | $328K | $257K | +78% |
| Share-based compensation | $3.2M | $3.7M | −$442K | -12% |
| Working capital & other | $8.6M | −$16.1M | $24.8M | — |
| Net loss absorbed | $8.9M | $9.1M | −$146K | -2% |
| Operating cash flow | $3.5M | −$21.2M | $24.7M | — |
| Free cash flow (OCF − capex) | $2.4M | −$21.3M | $23.7M | — |
| Capital expenditures | $1.1M | $62K | $1.0M | 17× |
Questions
How much did Akebia Therapeutics's revenue grow quarter over quarter in Q2 2026?
Akebia Therapeutics's revenue fell $4.4M (-8%) from $53.5M in Q1 2026 to $49.1M in Q2 2026.